DiogenX, a Marseille, France-based preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators for the treatment of type one diabetes (T1D), closed a seed financing round of €4.5m ($4.8M). Backers included Advent France Biotechnology (AFB), the Boehringer Ingelheim Venture Fund and the JDRF T1D Fund. In conjunction with the financing, Matthieu Coutet, … Continue reading DiogenX Raises €4.5M in Seed Financing